Urge IncontinenceESSENCENCT05882318
Effectiveness of eCoin at Sensory and Subsensory Amplitudes
A study testing eCoin Peripheral Neurostimulator System in people with Urge Incontinence, run by Valencia Technologies Corporation at 7 sites in United States.
Trial summary
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urge Incontinence
- What is being tested?
- eCoin Peripheral Neurostimulator System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 7 sitesUnited States
- Study dates
- 6 Jun 2023to 14 May 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individual with diagnosis of overactive bladder with urgency urinary incontinence - daily UUI with a predominantly urgency component
- Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
- Individual is determined to be a suitable surgical candidate by physician.
Who cannot join
- Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.
- Individual has predominantly stress urinary incontinence (greater than 1/3 of leaks on baseline diary are stress).
- Individual has clinically significant bladder outlet obstruction.
- Individual has an active urinary tract infection at time of enrollment or has had four or more symptomatic UTI's in the last 12 months.
- Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome that is actively being managed.
- Individual has post void residual greater than 200 cc.
Show all 23Show fewer
- Individual has an active diagnosis of bladder, urethral, or prostate cancer.
- Individual has had a prior anti-stress incontinence surgery within the last year.
- Individual has uncontrolled diabetes mellitus (Hemoglobin A1C>7).
- Individual is neutropenic or immune-compromised.
- Individual has lower extremity pathology such as:
- Previous surgery and/or significant scarring at the planned implant location
- Ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders
- Clinically significant peripheral neuropathy in the lower extremities
- Pitting edema at the implant location (≥ 2+ is excluded)
- Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg
- Moderate to severe varicose veins
- Open wounds or recent trauma
- Arterial and/or vasculitis disease in the lower extremities
- Chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region
- Individual has neurogenic bladder dysfunction.
- Individual is aware that he or she will need an MRI scan other than a head/neck/shoulder MRI during the study period.
- Any condition that, in the investigator's opinion, would preclude participation in the study (e.g., comorbidity that places subject at increased risk for surgical intervention, medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, such as morbid obesity, clotting or bleeding disorder)
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites
Institute for Female Pelvic Medicine
Allentown, Pennsylvania, 18103
The Iowa Clinic
Ankeny, Iowa, 50023
Genesis Research
Downey, California, 90241
Urology Associates of Central California
Fresno, California, 93720
Adult & Pediatric Urology P.C.
Omaha, Nebraska, 68114
Associated Urologists of North Carolina
Raleigh, North Carolina, 27612
Cypress Medical Research Center
Wichita, Kansas, 67226
About this study
Official title: Evaluating Effectiveness of Sensory and Subsensory Stimulation Amplitudes With eCoin® Tibial Nerve Stimulation in Urgency Urinary InContinence Episodes and Quality of Life
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). The main question it aims to answer is:
- The reduction in UUI episodes per day on a 3-day voiding diary in both groups after 3 months of therapy
Participants will be implanted with the eCoin device and randomized to either a sensory or subsensory stimulation group and complete voiding diaries and patient reported-outcomes through 3 months of therapy. After 3 months, subjects will be unblinded and reprogramming will be offered. Subjects will be followed for an additional month to a total of 4 months.
- Conditions
- Urge Incontinence
- Being tested
- eCoin Peripheral Neurostimulator System
- Keywords
- Neuromodulation, eCoin device, Stimulation, Tibial nerve
- Medical subject headings
- Urinary Incontinence, Urge
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eCoin Peripheral Neurostimulator SystemDevice
The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
| Study group | Role | What they receive |
|---|---|---|
| Sensory | Experimental | Participants in the sensory treatment arm will be programmed to their sensory threshold. Receives: Device: eCoin Peripheral Neurostimulator System |
| Subsensory | Experimental | Participants in the subsensory treatment arm will be programmed to approximately 75% of their sensory threshold. Receives: Device: eCoin Peripheral Neurostimulator System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in UUI Episodes Per Day
The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary.
A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline.
A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
Measured: 3 months post-activation
Secondary outcomes (4)
Change in UUI Episodes Per Day
Change in the number of urgency urinary incontinence episodes per day on a 3-day voiding diary.
A negative number shows a reduction in UUI episodes which means symptoms have improved since baseline.
A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
Measured: 2 months post-activation
Change in UUI Episodes Per Day
A secondary endpoint is to explore the change in UUI episodes per day on a 3-day voiding diary.
A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline.
A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
Measured: 4 months post-activation
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Change from baseline in the patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey.
Higher scores on the HRQL portion indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst).
A positive change in score indicates an improvement in quality of life.
Measured: 2 and 3 months post-activation
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Change from baseline in patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey.
Higher scores on the HRQL indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst).
A positive change in score indicates an improvement in quality of life.
Measured: 4 months post-activation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2023
- Study start6 Jun 2023
- Primary completion19 Apr 2024
- Study completion14 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Urge IncontinenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- Valencia Technologies Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05882318
- Sponsor's protocol ID
- 111-6133
- Acronym
- ESSENCE
- Status last verified
- Sep 2025
- First submitted
- 19 May 2023
- Last updated
- 3 Nov 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Effectiveness of Sensory and Subsensory Stimulation Amplitudes With eCoin® Tibial Nerve Stimulation in Urgency Urinary InContinence Episodes and Quality of Life
- ClinicalTrials.gov ID
- NCT05882318
- Acronym / sponsor ID
- ESSENCE / 111-6133
- Conditions
- Urge Incontinence
- Keywords
- Neuromodulation, eCoin device, Stimulation, Tibial nerve
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- Valencia Technologies CorporationIndustry (pharma, biotech, devices)
- Study start
- 6 Jun 2023 (actual)
- Primary completion
- 19 Apr 2024 (actual)
- Study completion
- 14 May 2024 (actual)
- First posted
- 31 May 2023 (actual)
- Results
- Posted 3 Nov 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). The main question it aims to answer is:
- The reduction in UUI episodes per day on a 3-day voiding diary in both groups after 3 months of therapy
Participants will be implanted with the eCoin device and randomized to either a sensory or subsensory stimulation group and complete voiding diaries and patient reported-outcomes through 3 months of therapy. After 3 months, subjects will be unblinded and reprogramming will be offered. Subjects will be followed for an additional month to a total of 4 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sensory | Experimental | Device: eCoin Peripheral Neurostimulator SystemParticipants in the sensory treatment arm will be programmed to their sensory threshold. |
| Subsensory | Experimental | Device: eCoin Peripheral Neurostimulator SystemParticipants in the subsensory treatment arm will be programmed to approximately 75% of their sensory threshold. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Individual with diagnosis of overactive bladder with urgency urinary incontinence - daily UUI with a predominantly urgency component
- Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
- Individual is determined to be a suitable surgical candidate by physician.
Key exclusion criteria (23 listed)
- Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.
- Individual has predominantly stress urinary incontinence (greater than 1/3 of leaks on baseline diary are stress).
- Individual has clinically significant bladder outlet obstruction.
- Individual has an active urinary tract infection at time of enrollment or has had four or more symptomatic UTI's in the last 12 months.
- Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome that is actively being managed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eCoin Peripheral Neurostimulator SystemThe eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management. | Device | Sensory, Subsensory |
Primary outcome
Change in UUI Episodes Per Day
Time frame: 3 months post-activation
The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
4 secondary outcomes
Change in UUI Episodes Per Day
Time frame: 2 months post-activation
Change in UUI Episodes Per Day
Time frame: 4 months post-activation
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Time frame: 2 and 3 months post-activation
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Time frame: 4 months post-activation
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Urge Incontinence
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
RecruitingPhase 2
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
Urinary Urge Incontinence, Stress Urinary Incontinence
Active, not recruiting
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
Overactive Bladder (OAB), Urinary Urgency
Recruiting
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
Urge Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing eCoin Peripheral Neurostimulator System in people with Urge Incontinence, run by Valencia Technologies Corporation at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in UUI Episodes Per Day (time frame: 3 months post-activation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2025.